Nihon Kohden (6849) Fundamentals 2026 — P/E 17.3x, Revenue Analysis | SniperIQ
Nihon Kohden (6849) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥246.9B, trading at ¥1543.50 on the JPX. This SniperIQ fundamentals page covers Nihon Kohden's valuation (P/E 17.3x, P/B 1.4x), profitability (net margin 6.2%), revenue (¥235.1B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Nihon Kohden's market cap?
Nihon Kohden (6849) has a market capitalization of approximately ¥246.9B, trading at ¥1543.50 on the JPX. Market cap moves with the live share price.
What is Nihon Kohden's P/E ratio?
Nihon Kohden's trailing twelve-month P/E ratio is 17.3x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Nihon Kohden?
Nihon Kohden runs a net profit margin of 6.2%, a gross margin of 51.1%, and an operating margin of 7.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Nihon Kohden generate?
Nihon Kohden reported revenue of ¥235.1B for fiscal year 2026, with net income of ¥14.5B and earnings per share (EPS) of 89.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Nihon Kohden pay a dividend?
Nihon Kohden offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Nihon Kohden financially healthy?
Nihon Kohden carries a debt-to-equity ratio of 0.14x and a current ratio of 3.60x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Nihon Kohden a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nihon Kohden (6849) the key facts are: market cap ¥246.9B, P/E 17.3x, revenue ¥235.1B, 52-week range 1323-1885.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Nihon Kohden's full fundamentals live
Get Nihon Kohden's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.